Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
Su Seong Woo(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center)
Cited by 72
Related Papers
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer
|Cancer Research|2021|155
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
|Endocrine Related Cancer|2008|148
First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
|Breast Cancer Research|2021|67
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
|Breast Cancer Research|2017|61